SCHEMBL573580

SCHEMBL573580

Brc1ccnc(N2CCNCC2)n1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.59
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
ACHE P22303 3/20 0.50
CHRNB2 P17787 2/20 0.49
CHRNA4 P43681 2/20 0.49
HRH3 Q9Y5N1 1/20 0.47
HRH1 P35367 1/20 0.46
HTR2C P28335 2/20 0.45
NCF1 P14598 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ROCK2 O75116 3/20 0.44
ROCK1 Q13464 1/20 0.44
CASP1 P29466 1/20 0.43
CASP4 P49662 1/20 0.43
CASP5 P51878 1/20 0.43
PLD1 Q13393 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421266 0.83 ACHE (0.46) ADRB1ALDH1A1ACHESMN1; SMN2
SCHEMBL28058217 0.83 DYRK1A (0.43) ADRB1KDM4EALDH1A1ACHE
SCHEMBL7019990 0.81 ACHE (0.45) ADRB1ALDH1A1ACHEUSP2SMN1; SMN2
SCHEMBL11113633 0.80 ADRB1 (0.61) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL5758330 0.79 ADRB1 (0.59) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL5797268 0.79 ADRB1 (0.59) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL31518606 0.79 ADRB1 (0.59) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL4501470 0.79 ADRB1 (0.59) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL7604060 0.79 ADRB1 (0.64) ADRB1KDM4EALDH1A1ACHEHRH3
SCHEMBL568877 0.79 PIK3CA (0.54) KDM4EALDH1A1ACHESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303497-A1 DEUTERATED 5-HT1A RECEPTOR AGONISTS CONRIG PHARMA APS (DK) 2013-11-14 US disclosed
EP-2601187-A1 DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS Conrig Pharma ApS (DK) 2013-06-12 EP disclosed
WO-2012016569-A1 DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS CONRIG PHARMA APS (DK) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303497-A1 DEUTERATED 5-HT1A RECEPTOR AGONISTS HTR1A, HTR1D, HTR5A ADRB1 31/4885KDM4E 3259/4885ALDH1A1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.